Table 2. Patient outcomes Patient .... | American Society of Hematology

Table 2.

Patient outcomes

Patient	Diagnosis	Disease status at CD8⁺ T_M cell infusion	CD8⁺ T_M cell dose, × 10⁶ cells per kg	3-month response after CD8⁺ T_M cell infusion	6-month response after CD8⁺ T_M cell infusion	Time from CD8⁺ T_M cell infusion to death or last follow-up, d	Status at last follow-up
1	AML	CR2	1.0	CR2	CR	1057	Dead
2	AML	Active disease	1.0	CR2	CR	591	Dead
3	AML	CR3	1.0	CR3	CR	1328	Alive in CR
4	AML	CR2	5.0	CR2	PD	430	Dead
5	CML	CR3	5.0	CR3	CR	1069	Alive in CR
6	CLL	Active disease	5.0	PD	PD	168	Dead
7	AML	Active disease	7.8	PD	PD	128	Dead
8	AML	Active disease	8.0	PD	PD	151	Dead
9	NHL	Active disease	10.0	PD	PD	495	Alive with disease
10	NHL	Active disease	5.2	SD	PD	412	Alive with disease
11	AML	CR2	10.0	CR2	CR	328	Alive in CR
12	AML	CR3	7.7	CR3	PD	286	Alive with disease
13	NHL	Active disease	10.0	SD	PD	194	Dead
14	MM	Active disease	10.0	PD	PD	221	Alive with disease
15	ALL	Active disease	10.0	PR	PD	118	Alive with disease

Patient	Diagnosis	Disease status at CD8⁺ T_M cell infusion	CD8⁺ T_M cell dose, × 10⁶ cells per kg	3-month response after CD8⁺ T_M cell infusion	6-month response after CD8⁺ T_M cell infusion	Time from CD8⁺ T_M cell infusion to death or last follow-up, d	Status at last follow-up
1	AML	CR2	1.0	CR2	CR	1057	Dead
2	AML	Active disease	1.0	CR2	CR	591	Dead
3	AML	CR3	1.0	CR3	CR	1328	Alive in CR
4	AML	CR2	5.0	CR2	PD	430	Dead
5	CML	CR3	5.0	CR3	CR	1069	Alive in CR
6	CLL	Active disease	5.0	PD	PD	168	Dead
7	AML	Active disease	7.8	PD	PD	128	Dead
8	AML	Active disease	8.0	PD	PD	151	Dead
9	NHL	Active disease	10.0	PD	PD	495	Alive with disease
10	NHL	Active disease	5.2	SD	PD	412	Alive with disease
11	AML	CR2	10.0	CR2	CR	328	Alive in CR
12	AML	CR3	7.7	CR3	PD	286	Alive with disease
13	NHL	Active disease	10.0	SD	PD	194	Dead
14	MM	Active disease	10.0	PD	PD	221	Alive with disease
15	ALL	Active disease	10.0	PR	PD	118	Alive with disease

CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.